BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals
(Reuters) -German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it said on Thursday, to boost its work on new mRNA-based cancer treatments.
Under the deal, which pairs two former rivals in the race to develop COVID-19 vaccines, CureVac shareholders stand to receive a premium of 55% over the three-month average share price, and leave them with a stake of about 4%-6% in BioNTech, the suitor said.
CureVac's Frankfurt-listed shares surged 27% to a five-month high, valuing the company at 1.04 billion euros ($1.2 billion), while BioNTech shares were down 2% by 1237 GMT.
The deal further underscores BioNTech's long-term pursuit of new cancer treatments as it aims to show that its success as Pfizer's COVID-19 vaccine partner, which left its balance sheet flush with billions of euros in cash, was not a fluke.
"With the acquisition, BioNTech aims to strengthen the research, development, manufacturing, and commercialization of investigational mRNA-based cancer immunotherapy," it said.
CureVac opted to focus on oncology about a year ago when it agreed to sell its remaining influenza and COVID-19 vaccine development to alliance partner GSK.
It had previously cut jobs as it sought to move beyond its failure to develop an mRNA-based COVID vaccine during the pandemic.
GERMAN BIOTECH CHAMPION
The agreement is also set to end CureVac's years-long legal fight over alleged mRNA patent infringement by BioNTech and for a share of vaccine revenues, where CureVac has made little progress.
CureVac shares were worth as much as 120 euros in December 2020 on hopes it would develop a COVID vaccine, more than double their initial public offer value in August of that year. They are now trading at 4.65 euros.
BioNTech won a major shot in the arm for its cancer drug activities last week when Bristol Myers Squibb agreed to pay up to $11.1 billion to jointly develop a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda.
Each CureVac share will be exchanged for about $5.46 in BioNTech American depositary shares, or ADS, but subject to a so-called collar mechanism, BioNTech said.
If the 10-day volume-weighted average price of BioNTech ADS shortly before the closing of the offer exceeds $126.55, the exchange ratio would be 0.04318, and if the price is lower than $84.37, the exchange ratio would be 0.06476.
BioNTech said the deal was supported by SAP SE co-founder and football investor Dietmar Hopp, who holds a stake of about 37% in CureVac.
The German government, owner of about 13% in CureVac for its financial backing during the pandemic, said it welcomed in principle the creation of a "new German biotech champion", and that it would review the offer.
($1 = 0.8624 euros)
(Additional reporting by Christian Kraemer; Editing by Friederike Heine, Jan Harvey and Emelia Sithole-Matarise)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Eater
4 hours ago
- Eater
Olmsted Is Closing in Prospect Heights
is the lead editor of the Northeast region with more than 20 years of experience as a reporter, critic, editor, and cookbook author. Chef Greg Baxtrom's standout Prospect Heights restaurant Olmsted will close August 17 after nearly a decade, he announced on Instagram. Olmsted, named for the famous landscape architect Fredrick Law Olmsted, who shaped the design of public spaces such as Prospect Park and Central Park in New York, opened to much fanfare in 2016. It was in the process of being saved, he said in his post, but efforts fell through. The announcement comes weeks after Baxtrom shuttered nearby Patti Ann's, the midwestern-leaning restaurant and bakery named after his mother. His remaining restaurant, 5 Acres, continues to run at Rockefeller Center. When it debuted, Olmsted 'was originally focused on steak-and-potatoes accessibility. But that isn't quite how it played out,' Eater wrote in sizing up how it became 'the hottest restaurant in Brooklyn' by 2017. A native of Chicago, Baxtrom opened his first restaurant in New York after working at acclaimed restaurants like Mugaritz in Spain, Atera and Per Se in New York, and Blue Hill at Stone Barns in Tarrytown. He once described himself as the '18-year-old with braces' working in the kitchen at Chicago's Alinea — and his Prospect Heights restaurant recently hosted the Alinea pop-up in honor of its 20th anniversary. Olmsted reflects Baxtrom's experiences, incorporating a working garden where diners could enjoy cocktails a stone's throw from live quail. His early menus featured dishes like watermelon sushi, the famous carrot crepe with clams, guinea hen two ways, and desserts like the frozen yogurt with whipped lavender honey. And while prices were more expensive than what had been in the neighborhood, he opened with prices that were 'low' compared to similar caliber restaurants, Pete Wells said in a two-star New York Times review. Baxtrom outlines some of his reasons to close in his Instagram post. 'Deciding to close a restaurant is never based on a single decision, but rather on many factors.' First, he cites his decision to get sober five years ago, when 'it became clear that I needed to prioritize my mental health over the restaurants if I was going to continue living. However, I find it challenging to practice this in real life.' In addition, the funding that would have kept the restaurant afloat fell through. 'If you are someone who appreciated what we created and would be interested in partnering with me to save Olmsted,' Baxtrom says on Instagram, 'please reach out.' Baxtrom told Eater that their pre-COVID expansion had become 'a bit of dead weight,' he says. The plan was to revert the restaurant to its original size. 'It just required investment. Beyond my means.' He also spoke of his hopes that Vanderbilt Avenue would have become more of a destination street, with Akhtar Nawab opening Alta Calidad in 2017, along with Joe Campanale and Erin Shambura opening nearby Fausto in the old Franny's space that same year. 'I hoped more big restaurateurs were going to follow.' Today, 'Vanderbilt is surprisingly a very difficult neighborhood to navigate,' he says. On his Instagram post, he says he has 'no desire to leave the industry I love; it brings me so much joy.' And over DM with Eater, Baxtrom says that perhaps he'd like to eventually open something in Chicago. 'My folks are getting older and I'd like to be there more.' Baxtrom demonstrated through his businesses that he is close with his parents. Patti Ann's that shuttered in July wasn't just an homage in name. It referenced the food he grew up on in his family's suburban Illinois household and featured an interior that nodded to his mother's career as a teacher — complete with a map on the wall as decor, cubbies that his father helped him build, and a report card on the table's performance that came with the check. Eater NY All your essential food and restaurant intel delivered to you Email (required) Sign Up By submitting your email, you agree to our Terms and Privacy Notice . This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Time Magazine
5 hours ago
- Time Magazine
Trump's Decision to Fire BLS Chief Echoes Putin's Strategies
President Donald Trump's firing of the Commissioner of the Bureau of Labor Statistics (BLS) on Friday afternoon just after she delivered a negative jobs report echoes the impulse of many leaders to shoot the messenger. Trump declared, 'I've had issues with the numbers for a long time. We're doing so well. I believe the numbers were phony like they were before the election and there were other times. So I fired her, and I did the right thing.' While Trump may or may not be friends with Vladimir Putin, he is clearly following the Russian President's HR staffing guidelines to eliminate lieutenants who bring bad news. As we've documented before, the Federal State Statistics Service (Rosstat) has a long history of manipulating official economic statistics to please Putin, 'bending over backward to correct bad numbers and burying unflattering statistics' under the pressure the Kremlin has exerted to corrupt statistical integrity, especially since Putin's invasion of Ukraine in 2022. The reliability of official statistics from China has also been brought into question, leading analysts to rely on a wide range of unofficial or proxy indicators to gauge the true state of the Chinese economy. Even China's former Premier, the late Li Keqiang, reportedly confided that he didn't trust official GDP numbers. Read More: What to Know About the Jobs Report That Led Trump to Fire the Labor Statistics Chief Like other strongmen, Trump has repeatedly shown a pattern of manipulating data to suit his preferred narrative. Trump's surprise firing of BLS Commissioner Erika McEntarfer has quickly caught the attention of technical market analysts and economists on both sides of the political spectrum. One side cheers the push to disrupt a slow, bureaucratic federal agency. The other side shouts in dismay over concerns about yet another example of Trump politicizing an apolitical institution. Both responses are warranted. The accuracy of BLS data has long been questioned as major revisions only come in months later. To their credit, the BLS, in addition to other statistical agencies, has publicly recognized a need to modernize its methodology. Unfortunately, though, the severity of job revisions has worsened since the COVID-19 era, with no successful program to address the issue. The downward revision on Friday of more than 250,000 jobs marked the most significant adjustment since the depths of the pandemic. However, Trump's accusations against the BLS of rigging the job numbers to make him and the Republican base look bad, and his subsequent firing of McEntarfer based on a belief that BLS revisions were politically motivated, are yet another step closer to authoritarianism. Introducing his latest conspiracy theory, the President went even further by suggesting McEntarfer, whose career spans two decades across Republican and Democratic Administrations, rigged the numbers 'around the 2024 presidential election' in then-Vice President Kamala Harris' favor. Trump conveniently fails to mention that his definition of 'around' was back in August 2024. Recall, the 2024 presidential election was a full three months later in November. Revisions are not unusual behavior by the BLS. They are a critical part of the natural process for developing an accurate picture of the largest, most dynamic economy in the world. The average size of job revisions since 2003 is not insignificant at 51,000 jobs. And, despite what Trump may want Americans to believe, his tariff policies have created an unprecedented level of uncertainty in the U.S. economy, comparable only to that of 2020, with many economists expecting a recession to follow as a result. Bloomberg reporting has pointed to a possible connection between the severity of negative job revisions and recessionary economic environments. The BLS has also been subjected to DOGE-led hiring constraints and other resource rescissions. In addition, the Trump Administration's disbanding of the Federal Statistics Advisory Committee in March both eliminated one of the main engines for enhancing agency performance and, perhaps, in what should have been a concerning harbinger, abolished the canary in the data integrity coal mine. Complaints about BLS methods are legitimate, like the reliance on enumerators over scanner data, and deserve attention, but this is not how to fix it. Read More: What Trump's Win Means for the Economy This is far from the first time Trump has subordinated statistical integrity to political theater. From crowd sizes to weather forecasts, vote counts to tariff formulas, Trump has discarded facts for fictions that play to his political favor. Trump doesn't just bend the truth—he twists the numbers until they resemble propaganda and then silences those who disagree. As CBS News titan Edward R. Murrow warned 65 years ago: 'To be persuasive, we must be believable. To be believable, we must be credible. To be credible, we must be truthful.'
The Hill
6 hours ago
- The Hill
Flu, COVID can reawaken dormant breast cancer cells: Study
Respiratory infections like COVID-19 and the flu can activate dormant cancer cells in breast cancer patients who are in remission, new research finds. The study, published in Nature, found that common viruses can reawaken small numbers of dormant breast cancer cells in the lungs. Researchers began investigating the link after the team noticed that U.K. patients who were in remission from breast cancer and tested positive for COVID later showed a two-fold increase in cancer-related deaths. They also analyzed a U.S. database that included nearly 37,000 patients and found that COVID infection was associated with a more than 40 percent increased risk of metastatic breast cancer in the lungs. Studies on mice found that influenza and COVID infections triggered dormant breast cancer cells after just days of infection. Within two weeks, researchers observed 'massive expansion' of the cancer cells into metastatic lesions by more than 100 times. Scientists have suspected that common viruses like Epstein-Barr can trigger some cancers. Human papillomavirus (HPV) is already documented to trigger cervical cancer. When it comes to breast cancer, however, research on human cells was limited, and it's not entirely known how the virus triggers the disease to spread. The findings suggest the body's immune response plays a role. After breast cancer goes into remission, a tiny number of cells remain dormant in lung, bone and liver tissue. Sometimes, inflammation can wake up the cells. In the mouse experiments, both influenza A and coronavirus only reawakened dormant cells if they triggered an inflammatory cytokine response. More research is needed to see if vaccination makes a difference when it comes to the possibility of reawakening dormant cells.
